Background: The prevalence and incidence of latent tuberculosis infection (LTBI) in patients with kidney transplant remains unclear. Methods: In this prospective study, we enrolled kidney transplant candidates (KTCs) and recipients (KTRs) from 2014 to 2018. We defined LTBI as a positive result of QuantiFERON-TB Gold In-tube (QFT). We analyzed the predictors for LTBI acquisition and followed QFT test for 2 years among those initially without LTBI. Results: Of 425 patients enrolled, 305 (71.8%) patients belonged to the KTC group and 120 (28.2%) to the KTR group. The initial QFT showed positive results in 33 (10.8%) and 25 (20.8%) in the KTC and KTR groups, respectively (p=0.007). The QFT response value in LTBI patients was higher in the KTR group than in the KTC group (1.85 vs. 1.06 IU/ml, p=0.046). Multivariate logistic regression showed that old age, absence of Bacillus Calmette-Guerin scar, and KTR group were independent factors for positive LTBI. For participants with initial negative QFT, positive QFT conversion within 2-year follow-up was higher after kidney transplantation (20%) than in KTCs (5.5%) (p=0.032). Conclusion: This study is the first cohort to follow up LTBI status in patients with kidney transplant and shows its higher prevalence and incidence in those belong to KTR. It indicates that surveillance of LTBI after renal transplantation is important.